The effect of stress- or lipopolysaccharide (LPS) endotoxin-induced release of ACTH, β-endorphin (β-END) and prolactin (PRL) was investigated in two groups of conscious male rats: (1) Rats pretreated with different H3 receptor agonists, which inhibit neuronal histamine (HA) synthesis and release, and (2) rats with bilateral posterior hypothalamic lesion, which destroys the histaminergic perikarya exclusively localized in the mammillary nuclei. The H3 receptor agonists R(α)methyl-HA, BP 2-94 or imetit injected intraperitoneally (ip) had no effect on basal secretion of ACTH or PRL but inhibited the ACTH and PRL responses to restraint stress and the ACTH response to LPS endotoxin. LPS had no effect on PRL secretion. The inhibitory effect of the agonists was prevented by prior ip administration of the H3 receptor antagonist thioperamide. Bilateral lesion of the posterior hypothalamus inhibited the ACTH, β-END and PRL responses to restraint stress, ether stress and LPS endotoxin, whereas sham operation had no effect compared to nonoperated control rats. In addition, posterior hypothalamic lesion inhibited the PRL response but not the ACTH and β-END responses to activation of serotonergic neurons induced by ip administration of the 5-HT precusor 5-hydroxytryptophan in combination with the 5-HT re-uptake inhibitor fluoxetine. Thus, serotonergic pathways were not damaged by the lesions. The present results support our previous findings that inhibition of neuronal HA synthesis by α-fluoromethylhistidine as well as blockade of H1 or H2 receptors inhibit the ACTH, β-END and PRL responses to stress and LPS endotoxin and further substantiate an important role of histaminergic neurons in the mediation of the stress-induced release of pituitary stress hormones. Furthermore, in accordance with our previous findings, the lesion experiments indicated the existence of an interaction between the histaminergic and serotonergic system in regulation of the stress- and LPS-induced PRL release.

Keywords:
Histamine receptors, Corticotropin, β-Endorphin, Prolactin, Adrenal steroids, Stress, Endotoxin, Serotonin
1.
Gala RR: The physiology and mechanisms of the stress-induced changes in prolactin secretion in the rat. Life Sci 1990;46:1407–1420.
2.
Berkenbosch F, Vermes I, Tilders FJ: The beta-adrenoceptor-blocking drug propranolol prevents secretion of immuoreactive beta-endorphin and alpha-melanocyte-stimulating hormone in response to certain stress stimuli. Endocrinology 1984;115:1051–1059.
3.
Kant GJ, Mougey EH, Meyerhoff JL: Diurnal variation in neuroendocrine response to stress in rats: Plasma ACTH, beta-endorphin, beta-LPH, corticosterone, prolactin and pituitary cyclic AMP responses. Neuroendocrinology 1986;43:383–390.
4.
Assenmacher I, Barbanel G, Gaillet S, Givalois L, Ixart G, Malaval F, Mekaouche M, Siaud P, Szafarczyk A: Central regulation of ACTH release in stress. Ann NY Acad Sci 1995;771:41–54.
5.
Minamitani N, Minamitani T, Lechan RM, Bollinger Gruber J, Reichlin S: Paraventricular nucleus mediates prolactin secretory responses to restraint stress, ether stress, and 5-hydroxy-L-tryptophan injection in the rat. Endocrinology 1987;120:860–867.
6.
Meyerhoff JL, Mougey EH, Kant GJ: Paraventricular lesions abolish the stress-induced rise in pituitary cyclic adenosine monophosphate and attenuate the increases in plasma levels of proopiomelanocortin-derived peptides and prolactin. Neuroendocrinology 1987;46:222–230.
7.
Bruhn TO, Plotsky PM, Vale WW: Effect of paraventricular lesions on corticotropin-releasing factor (CRF)-like immunoreactivity in the stalk-median eminence: Studies on the adrenocorticotropin response to ether stress and exogenous CRF. Endocrinology 1984;114:57–62.
8.
Linton EA, Tilders FJ, Hodgkinson S, Berkenbosch F, Vermes I, Lowry PJ: Stress-induced secretion of adrenocorticotropin in rats is inhibited by administration of antisera to ovine corticotropin-releasing factor and vasopressin. Endocrinology 1985;116:966–970.
9.
Tilders FJ, Berkenbosch F, Vermes I, Linton EA, Smelik PG: Role of epinephrine and vasopressin in the control of the pituitary-adrenal response to stress. Fed Proc 1985;44:155–160.
10.
Rivier C, Vale W: Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 1983;305:325–327.
11.
Plotsky PM, Bruhn TO, Vale W: Evidence for multifactor regulation of the adrenocorticotropin secretory response to hemodynamic stimuli. Endocrinology 1985;116:633–639.
12.
Ben Jonathan N: Dopamine: A prolactin-inhibiting hormone. Endocr Rev 1985;6:564–589.
13.
Abe H, Engler D, Molitch ME, Bollinger Gruber J, Reichlin S: Vasoactive intestinal peptide is a physiological mediator of prolactin release in the rat. Endocrinology 1985;116:1383–1390.
14.
Kjær A, Knigge U, Olsen L, Vilhardt H, Warberg J: Mediation of the stress-induced prolactin release by hypothalamic histaminergic neurons and the possible involvement of vasopressin in this response. Endocrinology 1991;128:103–110.
15.
Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M: Histaminergic transmission in the mammalian brain. Physiol Rev 1991;71:1–51.
16.
Knigge U, Warberg J: The role of histamine in the neuroendocrine regulation of pituitary hormone secretion. Acta Endocrinol Copenh 1991;124:609–619.
17.
Knigge U, Matzen S, Hannibal T, Jorgensen H, Warberg J: Involvement of histamine in the mediation of the stress-induced release of alpha-melanocyte-stimulating hormone in male rats. Neuroendocrinology 1991;54:646–652.
18.
Knigge U, Matzen S, Bach FW, Bang P, Warberg J: Involvement of histaminergic neurons in the stress-induced release of pro-opiomelanocortin-derived peptides in rats. Acta Endocrinol Copenh 1989;120:533–539.
19.
Soe-Jensen P, Knigge U, Garbarg M, Kjær A, Rouleau A, Bach FW, Schwartz JC, Warberg J: Responses of anterior pituitary hormones and hypothalamic histamine to blockade of histamine synthesis and to selective activation or inactivation of presynaptic histamine H3 receptors in stressed rats. Neuroendocrinology 1993;57:532–540.
20.
Kjær A, Knigge U, Madsen EL, Soe Jensen P, Bach FW, Warberg J: Insulin/hypoglycemia-induced adrenocorticotropin and beta-endorphin release: Involvement of hypothalamic histaminergic neurons. Endocrinology 1993;132:2213–2220.
21.
Knigge U, Kjær A, Jorgensen H, Garbarg M, Ross C, Rouleau A, Warberg J: Role of hypothalamic histaminergic neurons in mediation of ACTH and beta-endorphin responses to LPS endotoxin in vivo. Neuroendocrinology 1994;60:243–251.
22.
Knigge U, Matzen S, Warberg J: Histaminergic mediation of the stress-induced release of prolactin in male rats. Neuroendocrinology 1988;47:68–74.
23.
Arrang JM, Garbarg M, Quach TT, Dam Trung Tuong M, Yeramian E, Schwartz JC: Actions of beta-histine at histamine receptors in the brain. Eur J Pharmacol 1985;111:73–84.
24.
Arrang JM, Garbarg M, Schwartz JC: Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302:832–837.
25.
Panula P, Pirvola U, Auvinen S, Airaksinen MS: Histamine-immunoreactive nerve fibers in the rat brain. Neuroscience 1989;28:585–610.
26.
Inagaki N, Yamatodani A, Ando Yamamoto M, Tohyama M, Watanabe T, Wada H: Organization of histaminergic fibers in the rat brain. J Comp Neurol 1988;273:283–300.
27.
Jorgensen H, Knigge U, Warberg J: Effect of serotonin 5-HT1, 5-HT2, and 5-HT3 receptor antagonists on the prolactin response to restraint and ether stress. Neuroendocrinology 1992;56:371–377.
28.
Garbarg M, Tuong MD, Gros C, Schwartz JC: Effects of histamine H3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain. Eur J Pharmacol 1989;164:1–11.
29.
Garbarg M, Arrang JM, Rouleau A, Ligneau X, Tuong MD, Schwartz JC, Ganellin CR: S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J Pharmacol Exp Ther 1992;263:304–310.
30.
Rouleau A, Garbarg M, Ligneau X, Mantion C, Lavie P, Advenier C, Lecomte JM, Krause M, Stark H, Schunack W, Schwartz JC: Antinociceptive and anti-inflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug. J Pharmacol Exp Ther 1997;281:1085–1094.
31.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 2. New York, Academic Press, 1986.
32.
Wogensen L, Warberg J: Cyclic and diurnal alterations in the response of luteinizing hormone and prolactin to prostaglandin E2 during the rat oestrous cycle. Acta Endocrinol Copenh 1984;106:30–37.
33.
Knigge U, Bach FW, Matzen S, Bang P, Warberg J: Effect of histamine on the secretion of pro-opiomelanocortin-derived peptides in rats. Acta Endocrinol Copenh 1988;119:312–319.
34.
Fink K, Schlicker E, Neise A, Gothert M: Involvement of presynaptic H3 receptors in the inhibitory effect of histamine on serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1990;342:513–519.
35.
Fink K, Schlicker E, Gothert M: N-methyl-D-aspartate-stimulated noradrenaline release in rat brain cortex is modulated by presynaptic H3-receptors. Naunyn Schmiedebergs Arch Pharmacol 1994;349:113–117.
36.
Schlicker E, Fink K, Detzner M, Gothert M: Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect 1993;93:1–10.
37.
Jorgensen H, Knigge U, Kjær A, Warberg J: Interactions of histaminergic and serotonergic neurons in the hypothalamic regulation of prolactin and ACTH secretion. Neuroendocrinology 1996;64:329–336.
38.
Tuomisto J, Männistö P: Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985;37:249–332.
39.
Ryu JH, Yanai K, Iwata R, Ido T, Watanabe T: Heterogeneous distributions of histamine H3, dopamine D1 and D2 receptors in rat brain. Neuroreport 1994;5:621–624.
40.
Pollard H, Moreau J, Arrang JM, Schwartz JC: A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 1993;52:169–189.
41.
Niigawa H, Yamatodani A, Nishimura T, Wada H, Cacabelos R: Effect of neurotoxic lesions in the mammmillary bodies on the distribution of brain histamine. Brain Res 1988;459:183–186.
42.
Airaksinen MS, Alanen S, Szabat E, Visser TJ, Panula P: Multiple neurotransmitters in the tuberomammillary nucleus: Comparison of rat, mouse, and guinea pig. J Comp Neurol 1992;323:103–116.
43.
Van de Kar LD: Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu Rev Pharmacol Toxicol 1991;31:289–320.
44.
Calogero AE: Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron. Ann NY Acad Sci 1995;771:31–40.
45.
Kamei C, Okumura Y, Tsujimoto S, Tasaka K: Role of hypothalamic histamine in stimulating the corticosterone release in rats. Arch Int Pharmacodyn Ther 1993;325:35–50.
46.
Ivanisevic Milovanovic OK, Musicki BD: Luteinization of ovaries and gonadotrophin and prolactin secretion in rats with posterior hypothalamic lesions. Endocr Regul 1992;26:89–93.
47.
Schultz NJ, Terasawa E: Posterior hypothalamic lesions advance the time of the pubertal changes in luteinizing hormone release in ovariectomized female rhesus monkeys. Endocrinology 1988;123:445–455.
48.
Beltramino C, Taleisnik S: Inhibitory influence of the nuclei of the posterior hypothalamus on the pro-oestrous surge of LH. Acta Endocrinol Copenh 1984;105:433–440.
49.
Takano S, Negoro H, Honda K, Higuchi T: Lesion and electrophysiological studies on the hypothalamic afferent pathway of the milk ejection reflex in the rat. Neuroscience 1992;50:877–883.
50.
Alvarez XA, Franco A, Fernandez Novoa L, Cacabelos R: Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels. Agents Actions 1994;41:C70–2.
51.
Alvarez XA, Franco A, Fernandez Novoa L, Cacabelos R: Effects of neurotoxic lesions in the posterior hypothalamic region on psychomotor activity and learning. Agents Actions 1994;43:21–23.
52.
Klapdor K, Hasenohrl RU, Huston JP: Facilitation of learning in adult and aged rats following bilateral lesions of the tuberomammillary nucleus region. Behav Brain Res 1994;61:113–116.
53.
Wagner U, Segura Torres P, Weiler T, Huston JP: The tuberomammillary nucleus region as a reinforcement inhibiting substrate: Facilitation of ipsihypothalamic self-stimulation by unilateral ibotenic acid lesions. Brain Res 1993;613:269–274.
54.
Monti JM: Involvement of histamine in the control of the waking state. Life Sci 1993;53:1331–1338.
55.
Denoyer M, Sallanon M, Buda C, Delhomme G, Dittmar A, Jouvet M: The posterior hypothalamus is responsible for the increase of brain temperature during paradoxical sleep. Exp Brain Res 1991;84:326–334.
56.
Millan MJ, Przewlocki R, Millan MH, Herz A: Evidence for a role of the ventromedial posterior hypothalamus in nociceptive processes in the rat. Pharmacol Biochem Behav 1983;18:901–907.
57.
Maskrey M, Hinrichsen CF: Respiratory responses to combined hypoxia and hypothermia in rats after posterior hypothalamic lesions. Pflügers Arch 1994;426:371–377.
58.
Bell J, Gruenthal M, Finger S, Mangold R: Effects of one- and two-stage lesions of the posterior hypothalamus on temperature regulation in the rat. Brain Res 1981;219:451–455.
59.
Przuntek H, Philippu A: Reduced pressor responses to stimulation of the locus coeruleus after lesion of the posterior hypothalamus. Naunyn Schmiedebergs Arch Pharmacol 1973;276:119–122.
60.
Tanabe S, Bunag RD: Aging escalates baroreceptor reflex suppression by the posterior hypothalamus in rats. Hypertension 1991;17:80–90.
61.
Schagen FH, Knigge U, Kjær A, Larsen PJ, Warberg J: Involvement of histamine in suckling-induced release of oxytocin, prolactin and adrenocorticotropin in lactating rats. Neuroendocrinology 1996;63:550–558.
62.
Kjær A, Larsen PJ, Knigge U, Warberg J: Histaminergic activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 1994;135:1171–1177.
63.
Kjær A, Knigge U, Plotsky PM, Bach FW, Warberg J: Histamine H1 and H2 receptor activation stimulates ACTH and beta-endorphin secretion by increasing corticotropin-releasing hormone in the hypophyseal portal blood. Neuroendocrinology 1992;56:851–855.
64.
Kjær A, Knigge U, Bach FW, Warberg J: Histamine- and stress-induced secretion of ACTH and beta-endorphin: Involvement of corticotropin-releasing hormone and vasopressin. Neuroendocrinology 1992;56:419–428.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.